The only ophthalmic pharmaceutical company on the list

HONG KONG, 30 September 2021 – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs, is pleased to announce that Zhaoke Ophthalmology is selected as a “China Top 30 Innovative Small Molecule Drug Developers” on the “2020 China Top 100 Innovative Biotech Companies List”, organised by the Chinese leading healthcare information platform Menet. Zhaoke Ophthalmology is also the only ophthalmic pharmaceutical company on the list.

The “2020 China Top 100 Innovative Biotech Companies List (2020年度「中国生物医药企业创新力百强系列榜单」” was revealed on 26 September, at the Suzhou Jinji Lake International Conference Centre (苏州金鸡湖国际会议中心), during the sixth China BioMed Innovation and Investment Conference (CBIIC). Dr. Lit-Fui Lau, President and Chief Operating Officer of Zhaoke Ophthalmology, attended the conference and received the award on behalf of Zhaoke Ophthalmology.